How cancer cells hijack your body's genetic 'off' switches
In short: DNA methylation acts as a biological dimmer switch, silencing genes or keeping them active without altering the underlying code. In cancer, this system breaks down: some regions lose their marks entirely while others are locked shut, effectively turning off the very genes meant to stop tumors from growing.
In healthy mammalian cells, DNA methylation is a fundamental epigenetic mechanism where a methyl group attaches to the 5th carbon of cytosine within CpG dinucleotides. This process regulates gene expression and chromatin organization. In normal somatic cells, about 80% of these cytosines are methylated. While methylation on gene bodies often correlates with active expression, high levels of methylation at CpG-rich promoters—known as CpG islands—typically cause transcriptional repression. These islands remain unmethylated in healthy states to ensure stability throughout evolution.
Cancer disrupts this delicate equilibrium through two primary malfunctions. First, it causes global hypomethylation, particularly in repeat-rich intergenic regions. Second, it creates localized hypermethylation at specific CpG islands associated with tumor suppressor genes. By 'silencing' these suppressors, cancer cells can bypass natural growth limits. Research suggests that the loss of DNA methylation alone, even without significant DNA damage, can push cancer cells into a state of non-canonical senescence, offering a potential new avenue for therapeutic intervention.
The machinery responsible for maintaining these marks involves key enzymes like DNMT1 and UHRF1. In healthy replication, UHRF1 recognizes hemimethylated DNA and recruits DNMT1 to ensure the 'memory' of methylation is passed to daughter cells. However, in cancer, various factors—including inflammation, DNA damage, and specific miRNAs—can interfere with this machinery or interact with histone modifications (like H3K4me2/3) to drive aberrant patterns. Understanding these molecular origins is essential for developing biomarkers that can diagnose and manage the disease.
This field of study highlights a shift from viewing cancer as purely a sequence mutation to understanding it as an epigenetic crisis. Because methylation is dynamic, cells exist in a constant state of equilibrium between deposition and removal. When this balance shifts, the cell's identity changes, providing both a challenge for treatment and a target for precision medicine.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: DNA Methylation and Cancer
- Also: Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications
- Also: DNA methylation protects cancer cells against senescence - Nature Communications
To cite this card, link to https://intellectplus.co.uk/app/science-dna-methylation-and-cancer.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Science · Latest · A–Z · All topics
